Skip to content

This website is a third-party information service. It does not provide medical care or operate a treatment facility.

Phase 3 Cancer Trials

Wisconsin

Phase 3 cancer trials in Wisconsin

93 Phase 3 cancer studies are recruiting participants at sites in 61 cities across Wisconsin as of November 18, 2026, according to ClinicalTrials.gov.

Call (888) 306-7888
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Browse Wisconsin by city

Cities with the most studies recruiting right now.

Every Wisconsin city with a recruiting study

By research area: Lung Cancer (25), Breast Cancer (21), Lymphoma (19), Prostate Cancer (15), Pancreatic Cancer (9), Melanoma (4).

Milwaukee (49), Madison (46), Green Bay (29), Marshfield (27), Stevens Point (24), La Crosse (23), Waukesha (22), Ashland (21), Eau Claire (21), Mukwonago (21), Oconomowoc (21), Sheboygan (21), Sturgeon Bay (21), Weston (21), Antigo (18), Appleton (18), Menomonee Falls (18), Wausau (18), West Bend (18), Wisconsin Rapids (18), Oak Creek (17), Oshkosh (17), Rhinelander (17), Rice Lake (17), Grafton (16), Oconto Falls (16), Racine (16), Wauwatosa (16), Burlington (15), Germantown (15), Kenosha (15), Marinette (15), Summit (15), West Allis (15), Minocqua (14), Two Rivers (14), New Richmond (13), Medford (12), Cudahy (11), Johnson Creek (10), Neenah (10), New Berlin (10), Spooner (10), Superior (10), Hayward (8), Janesville (7), Franklin (6), Shawano (6), Berlin (5), Brookfield (5), Chilton (5), Mequon (5), Waupaca (5), New London (4), Chippewa Falls (2), Fond du Lac (2), Ladysmith (2), Greenfield (1), Hudson (1), Neillsville (1), West Salem (1).

The number after each city is how many studies have a recruiting site there. A study with sites in several cities is counted in each one.

Breast cancer: recently updated in Wisconsin

Basic details from each study's public record (the 12 most recently updated of 93). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Recruiting in
    Madison
    Registry record
    NCT06393374 · updated
  2. Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Recruiting in
    Appleton · Ashland · Green Bay · and 11 more U.S. locations
    Registry record
    NCT07391774 · updated
  3. A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Recruiting in
    Madison
    Registry record
    NCT06966700 · updated

Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Wisconsin on ClinicalTrials.gov.

Lung cancer: recently updated in Wisconsin

  1. Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Recruiting in
    Antigo · Ashland · Eau Claire · and 15 more U.S. locations
    Registry record
    NCT06498635 · updated
  2. Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Recruiting in
    Ashland · Green Bay · Menomonee Falls · and 8 more U.S. locations
    Registry record
    NCT07388524 · updated
  3. A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Recruiting in
    La Crosse
    Registry record
    NCT07513376 · updated

Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Wisconsin on ClinicalTrials.gov.

Prostate cancer: recently updated in Wisconsin

  1. Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

    • Phase 3
    • Ages 18 and older
    • Male participants
    Sponsor
    ECOG-ACRIN Cancer Research Group
    Recruiting in
    Antigo · Eau Claire · Johnson Creek · and 10 more U.S. locations
    Registry record
    NCT04423211 · updated

Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in Wisconsin on ClinicalTrials.gov.

Melanoma: recently updated in Wisconsin

  1. Comparing the Effectiveness of Less Invasive Procedures With the Current Standard of Care for the Treatment of Older Adults With Early-Stage Melanoma

    • Phase 3
    • Ages 75 and older
    • All sexes
    Sponsor
    ECOG-ACRIN Cancer Research Group
    Recruiting in
    Marshfield · Menomonee Falls · Milwaukee · and 4 more U.S. locations
    Registry record
    NCT07068074 · updated

Source: ClinicalTrials.gov. Data processed . See every melanoma study recruiting in Wisconsin on ClinicalTrials.gov.

Lymphoma: recently updated in Wisconsin

  1. Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Recruiting in
    Appleton · Ashland · Eau Claire · and 17 more U.S. locations
    Registry record
    NCT06337318 · updated
  2. SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Nuvation Bio Inc.
    Recruiting in
    Madison
    Registry record
    NCT05303519 · updated
  3. A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Recruiting in
    Madison
    Registry record
    NCT06136559 · updated
  4. Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy

    • Phase 3
    • Ages 18 to 75
    • All sexes
    Sponsor
    Eastern Cooperative Oncology Group
    Recruiting in
    Madison · Marshfield · Menomonee Falls · and 7 more U.S. locations
    Registry record
    NCT06724237 · updated

Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in Wisconsin on ClinicalTrials.gov.

Ask about studies in Wisconsin

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 18, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that are in Phase 3, including combined Phase 2/3, as each study is coded in the registry.

Phase 3 Cancer Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 306-7888

or send a short form

How should we reach you?

Call